Company logo

CCXI - ChemoCentryx, Inc.

NASDAQ -> Healthcare -> Biotechnology
Mountain View, United States

CCXI price evolution
CCXI
Balance Sheet
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Current assets
Cash $77.2 $68.55 $32.3 $56.18
Short term investments $235.4 $307.74 $404.27 $415.21
Net receivables $0.17 $10.14 $0.17 $0.1
Inventory
Total current assets $317.13 $390.64 $441.57 $474.44
Long term investments $90.03 $47.88 $23.8 $14.46
Property, plant & equipment $59.07 $59.13 $52.07 $42.73
Goodwill & intangible assets
Total noncurrent assets $150.54 $108.47 $77.33 $58.6
Total investments $325.43 $355.61 $428.07 $429.66
Total assets $467.67 $499.11 $518.9 $533.04
Current liabilities
Accounts payable $11.09 $10.93 $12.88 $8.87
Deferred revenue $34.72 $36.38 $36.59 $34.63
Short long term debt $12.98 $9.61 $6.3 $3.07
Total current liabilities $55.38 $54.73 $51.56 $46.86
Long term debt $56.74 $58.98 $56.77 $55.7
Total noncurrent liabilities $82.02 $83.38 $81.73 $81.36
Total debt $69.73 $68.59 $63.07 $58.76
Total liabilities $137.4 $138.11 $133.29 $128.22
Shareholders' equity
Retained earnings -$554.26 -$515.05 -$485.34 -$455.47
Other shareholder equity -$0.08 -$0.01 $0.11 $0.27
Total shareholder equity $330.27 $361 $385.61 $404.82
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Current assets
Cash $32.3 $39.18 $28.09 $40.02
Short term investments $404.27 $133.61 $148.9 $87.27
Net receivables $0.17 $0.18 $2.06 $51.09
Inventory
Total current assets $441.57 $174.36 $181.38 $179.83
Long term investments $23.8 $29.45 $7.93
Property, plant & equipment $52.07 $3.86 $1.54 $1.21
Goodwill & intangible assets
Total noncurrent assets $77.33 $34.72 $1.93 $9.5
Total investments $428.07 $163.06 $148.9 $95.2
Total assets $518.9 $209.08 $183.31 $189.33
Current liabilities
Accounts payable $12.88 $1.53 $0.97 $1.4
Deferred revenue $36.59 $100.84 $134.56 $95.16
Short long term debt $6.3
Total current liabilities $51.56 $59.08 $64.4 $32.94
Long term debt $56.77 $19.79 $19.69 $4.68
Total noncurrent liabilities $81.73 $84 $104.18 $77.12
Total debt $63.07 $19.79 $19.69 $4.68
Total liabilities $133.29 $143.08 $168.57 $110.06
Shareholders' equity
Retained earnings -$485.34 -$429.99 -$374.5 -$289.2
Other shareholder equity $0.11 $0.32 -$0.2 -$0.12
Total shareholder equity $385.61 $66 $14.74 $79.27
Income Statement
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Revenue
Total revenue $1.81 $10.35 $4.36 $5.08
Cost of revenue
Gross Profit $1.81 $10.35 $4.36 $5.08
Operating activities
Research & development $20.85 $23.42 $21.23 $18.58
Selling, general & administrative $19.7 $16.26 $12.71 $10.36
Total operating expenses $40.55 $39.68 $33.94 $28.94
Operating income -$38.74 -$29.33 -$29.58 -$23.86
Income from continuing operations
EBIT -$38.51 -$29.02 -$29.18 -$23.36
Income tax expense
Interest expense $0.69 $0.69 $0.7 $0.7
Net income
Net income -$39.21 -$29.71 -$29.88 -$24.06
Income (for common shares) -$39.21 -$29.71 -$29.88 -$24.06
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Revenue
Total revenue $64.89 $36.13 $42.88 $82.5
Cost of revenue
Gross Profit $64.89 $36.13 $42.88 $82.5
Operating activities
Research & development $77.88 $70.28 $62.74 $49.49
Selling, general & administrative $42.19 $24.16 $20.41 $16.51
Total operating expenses $120.07 $94.43 $83.14 $66
Operating income -$55.18 -$58.3 -$40.27 $16.49
Income from continuing operations
EBIT -$52.71 -$53.34 -$36.74 $17.86
Income tax expense $17.86
Interest expense $2.64 $2.15 $1.22 $0
Net income
Net income -$55.36 -$55.49 -$37.97 $17.86
Income (for common shares) -$55.36 -$55.49 -$37.97 $17.86
Cash Flow
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Net income -$39.21 -$29.71 -$29.88 -$24.06
Operating activities
Depreciation $1.57 $0.71 $0.96 $0.83
Business acquisitions & disposals
Stock-based compensation $7.7 $8.08 $7.01 $5.95
Total cash flows from operations -$17.85 -$21.57 -$19.22 -$16.16
Investing activities
Capital expenditures -$3.3 -$10.88 -$9.27 -$4.01
Investments $29.06 $71.55 $0.77 -$258.84
Total cash flows from investing $25.77 $60.67 -$8.5 -$262.85
Financing activities
Dividends paid
Sale and purchase of stock $1 $2.16 $3.85 $1.98
Net borrowings
Total cash flows from financing $0.74 -$2.85 $3.85 $1.98
Effect of exchange rate
Change in cash and equivalents $8.66 $36.25 -$23.88 -$277.03
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Net income -$55.36 -$55.49 -$37.97 $17.86
Operating activities
Depreciation $2.77 $1.64 $0.51 $0.42
Business acquisitions & disposals
Stock-based compensation $22.91 $11.64 $10.83 $8.75
Total cash flows from operations -$81.14 -$70.12 $16.44 $4.88
Investing activities
Capital expenditures -$15.41 -$0.79 -$0.84 -$0.72
Investments -$266.95 -$11.74 -$52.23 $16.32
Total cash flows from investing -$282.36 -$12.53 -$53.07 $15.6
Financing activities
Dividends paid
Sale and purchase of stock $355.97 $96.13 $10.47 $3.27
Net borrowings $4.36 $14.91 $4.68
Total cash flows from financing $356.62 $94.82 $24.7 $7.52
Effect of exchange rate
Change in cash and equivalents -$6.88 $12.17 -$11.93 $28
Fundamentals
Market cap $2.59B
Enterprise value $2.58B
Shares outstanding 69.90M
Revenue $21.61M
EBITDA -$115.99M
EBIT -$120.07M
Net Income -$122.86M
Revenue Q/Q -96.33%
Revenue Y/Y -71.60%
P/E ratio -21.10
EV/Sales 119.61
EV/EBITDA -22.28
EV/EBIT -21.52
P/S ratio 119.95
P/B ratio 7.85
Book/Share 4.73
Cash/Share 1.10
EPS -$1.76
ROA -24.34%
ROE -33.17%
Debt/Equity 0.35
Net debt/EBITDA -0.52
Current ratio 5.73
Quick ratio 5.73